New hope for lung cancer patients when first targeted drug stops working
NCT ID NCT07199010
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study looks at how well the drug taletrectinib works in people with advanced ROS1-positive non-small cell lung cancer whose cancer has gotten worse after treatment with entrectinib. Researchers will follow 50 patients in real-world clinics to see if the drug shrinks tumors and how long it keeps the cancer under control. The goal is to gather practical information on effectiveness and safety outside of a strict clinical trial setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital (The East Hospital Affiliated to Tongji University)
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Taletrectinib (a targeted cancer drug)
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to an earlier drug.
What could go wrong
This is an early, small observational study (50 people) that just watches what happens in real-world practice. It may not prove the drug works better than other options, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.